News2019-09-25T15:29:32-07:00

News

8April 2020

Building On Immunotherapy, Preventing Acquired Resistance Are Next Steps in Lung Cancer Research

Research, Treatments|

*March 2020* Checkpoint inhibitors and next-generation TKIs have demonstrated improved survival outcomes in patients with non–small cell lung cancer (NSCLC); however, ongoing research efforts are looking to build upon the benefits with combination strategies and prevent acquired resistance to

8April 2020

Cause of Resistance to 3rd-Gen EGFR-TKIs Varied in T790M-Mutated NSCLC

Research, Treatments|

*March 2020* Targeted sequencing of patients with acquired resistance to third-generation EGFR tyrosine kinase inhibitors (TKIs) for EGFR T790M-mutant non-small cell lung cancer (NSCLC) revealed that resistance is associated with diverse pathways. The retrospective study looked at the genomic

8April 2020

FDA Grants Breakthrough Therapy Designation to JNJ-6372 in Metastatic Non-Small Cell Lung Cancer

Research, Treatments|

*March 2020* The US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for JNJ-6372 to Janssen Pharmaceutical, a Johnson & Johnson Company. NJ-6372 is an investigational treatment for metastatic non-small cell lung cancer (mNSCLC) with epidermal growth

1April 2020

Tumor Analyses Reveal Squamous Transformation and Off-Target Alterations As Early Resistance Mechanisms to First-line Osimertinib in EGFR-Mutant Lung Cancer

Research, Treatments|

*January 2020* Among 62 patients who met eligibility critieria, histologic transformation, primarily squamous transformation, was identified in 15% of first-line osimertinib cases and 14% of later-line cases. Nineteen percent (5/27) of patients treated with first-line osimertinib had off-target genetic

4March 2020

Scientists link common immune cell to failure of checkpoint inhibitors in lung cancer

Research, Treatments|

*December 2019* Checkpoint inhibitors come with a huge caveat: They only help a small subset of patients. Doctors struggle to predict who these patients are and—just as important—who they aren't. Results from a new study published Dec. 19 in

4March 2020

FDA Grants Fast Track Designation to Oncoprex Combination for NSCLC

Research, Treatments|

*January 2020* Oncoprex in combination with osimertinib (Tagrisso) received fast track designation from the FDA to treat patients with non-small cell lung cancer (NSCLC) with EFGR mutations that progressed after treatment with osimertinib alone, according to Genprex, Inc., the immunogene therapy’s

4March 2020

FDA Schedules ODAC Meeting on Ramucirumab/Erlotinib in Frontline EGFR+ NSCLC

Research, Treatments|

*January 2020* The FDA has scheduled an Oncologic Drugs Advisory Committee (ODAC) hearing for February 26, 2020, to discuss data supporting a supplemental biologics license application (sBLA) for intravenous ramucirumab (Cyramza) injection for use in combination with erlotinib (Tarceva)

18January 2020

Lazertinib Shows Promising Antitumor Activity in Patients With EGFR+ NSCLC

Research, Treatments|

*December 2019* With the inevitability of resistance to first- and second-generation EGFR tyrosine kinase inhibitors (TKIs) in patients with EGFR-mutant non–small cell lung cancer (NSCLC), novel options like lazertinib (YH25448), an irreversible, third-generation, mutant-selective, EGFR TKI are being explored. Lazertinib

18January 2020

Bridge Biotherapeutics Files Investigational New Drug Application for BBT-176, an EGFR TKI for NSCLC

Research, Treatments|

*December 2019* SEONGNAM, South Korea, Dec. 19, 2019 /PRNewswire/ -- Bridge Biotherapeutics Inc., a clinical stage biotech company headquartered in Seongnam, South Korea, announced that the company filed an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) and the

18January 2020

Osimertinib promising for EGFR-mutant NSCLC with leptomeningeal metastases

Research, Treatments|

*December 2019* Patients with EGFR-mutant (m) non-small-cell lung cancer (NSCLC) and leptomeningeal metastases (LM) respond favorably to high daily doses of osimertinib, phase 1 BLOOM study data suggest. Myung-Ju Ahn (Sungkyunkwan University School of Medicine, Seoul, Republic of Korea) and

18January 2020

Dana-Farber Cancer Institute to Establish Chen-Huang Center for EGFR Mutant Lung Cancers

Funding, Research|

*January 2020* Dana-Farber Cancer Institute will create the Chen-Huang Center for EGFR (epidermal growth factor receptor) Mutant Lung Cancers to stimulate research, promote clinical trials, and strengthen the Institute’s capabilities for studying and treating lung cancer. The Chen-Huang Center

20December 2019

Project PRIORITY: Why it matters to the EGFR-positive lung cancer community

Advocacy, Coping With Cancer, Research|

*December 2019* Project PRIORITY (Patient Reported Initiative On Resistance, Incidence, Treatment studY), is a collaboration between LUNGevity Foundation and the EGFR Resisters—a grassroots, patient-driven community dedicated exclusively to changing EGFR-positive lung cancer into a manageable chronic disease. Goal of Project

8November 2019

Analyzing Best Practices for Targeting EGFR Resistance Mutations in EGFR+ NSCLC

Research, Treatments|

*June 2019*  by Nichole Tucker for Targeted Oncology Tyrosine kinase inhibitors (TKIs) targeting the epidermal growth factor receptor (EGFR) have made a well-documented impact on outcomes for patients with non–small cell lung cancer (NSCLC) who harbor EGFR mutations; the challenge is

25September 2019

Hypofractionated EGFR tyrosine kinase inhibitor limits tumor relapse through triggering innate and adaptive immunity

Research, Treatments|

*August 2019*  Science Immunology Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are a first-line therapy for rapidly killing tumors such as those associated with non–small cell lung cancer by blocking oncogenic receptor signaling, but tumor relapse often

12August 2019

In Depth Overview of Tyrosine Kinase Inhibitor Treatment of EGFR+ Lung Cancer

Research, Treatments|

*July 2019* by Dr. C.H. Weaver M.D. for CancerConnect. Tagrissio, Tarceva and other TKI therapy for EGFR + NSCLC continue to evolve and improve survival.Advances in cancer research have highlighted the importance of understanding the specific characteristics of each person’s cancer. These

12August 2019

Cumulative Antibiotic Use Significantly Decreases Efficacy of Checkpoint Inhibitors in Patients with Advanced Cancer

Research|

*July 2019* The Oncologist. With the advent of immunotherapy, substantial progress has been made in improving outcomes for patients with advanced cancer. However, not all patients benefit equally from treatment, and confounding immune‐related issues may have an impact. Several

18June 2019

High PD-L1 expression correlates with primary resistance to EGFR-TKIs in treatment naïve advanced EGFR-mutant lung adenocarcinoma patients

Research, Treatments|

*January 2019*  Lung Cancer.   This small study from Taiwan was performed to investigate the relationship between PD-L1 expression levels and resistance to EGFR-TKI medications in patients with treatment-naïve advanced EGFR mutant lung adenocarcinoma. (By treatment naïve, these patients had

17March 2019

Deep Dive: Afatinib+Cetuximab for T790M Neg Patients With Acquired Resistance

Research, Treatments|

*March 2019*  This is an overview (written by Donald Ox) of the current EGFR TKIs and acquired resistance leading to the effectiveness of the afatinib + cetuximab combo treatment especially useful for T790M negative patients who developed acquired resistance to

14March 2019

Novel and Innovative Approach to Monitoring Disease Progression in Cancer on Horizon  

Research, Treatments|

*March 2019* Currently available for research purposes only, the Signatera (RUO) is the first ctDNA (circulating tumor DNA) assay custom-built for treatment monitoring and minimal residual disease (MRD) assessment. The test is being developed by Natera and is not yet

3February 2019

A cancer researcher reflects on the evolution of lung cancer therapies

Research, Treatments|

*January 2019* Harvard Health Publishing, Harvard Medical School, by Stephen Lyons.   When Dr. Lecia Sequist was undergoing her training to become a medical oncologist at Massachusetts General Hospital (MGH) in the early 2000s, the treatments available for lung cancer

3February 2019

Continuing Osimertinib Treatment After Progression Prolongs Survival Benefit in NSCLC

Research, Treatments|

*January 25, 2019* Targeted Oncology, Tony Berberabe. Patients who continued receiving osimertinib (Tagrisso) after their non–small cell lung cancer (NSCLC) had progressed demonstrated a prolonged benefit beyond the initial progression event, according to a retrospective analysis of 118 patients from

5January 2019

OncTalk 2018 – Local Therapies for Metastatic Lung Cancer – Who, What, Why, When and How?

Research, Treatments|

*November 10, 2018* GRACE partnered with Swedish Cancer Institute to present a discussion on Local Therapies for Metastatic Lung Cancer. Videos from the live webcast: Newer Technologies in Radiation; Novel Indications for Local Therapy in Advanced NSCLC; Systemic Therapies

22November 2018

PATIENTS LAUNCH NEW STUDY TO SHED LIGHT ON EGFR-POSITIVE LUNG CANCERS

Research, Treatments|

Scientists, physicians and patients collaborate to improve treatment for rare cancer SAN CARLOS, CA (November 14, 2018) — The Addario Lung Cancer Medical Institute (ALCMI), Champions Oncology and EGFR Resisters today announced the launch of a new study to create a novel bank of patient derived

22November 2018

Overcoming EGFR G724S-mediated osimertinib resistance through unique binding characteristics of second-generation EGFR inhibitors

Research, Treatments|

*NATURE COMMUNICATIONS | (2018) 9:4655 | DOI: 10.1038/s41467-018-07078-0 | www.nature.com/naturecommunications * The emergence of acquired resistance against targeted drugs remains a major clinical challenge in lung adenocarcinoma patients. In a subgroup of these patients we identified an association between

Living with EGFR

Supporting Research

Finding Hope

Join Us.

Do you (or a loved one) have EGFR-positive lung cancer? Your voice matters! By participating in this survey, YOU could help shape EGFR-positive lung cancer treatment development and future research, ensuring that they address what is most important to the EGFR-positive lung cancer community.